Routine screening for CKD should be done in asymptomatic adults … selectively

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 11, 2014, Pages 1988-1992

  Berns, Jeffrey S ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE;

AGE; ALBUMINURIA; ARTICLE; ASYMPTOMATIC DISEASE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL DECISION MAKING; COST CONTROL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; END STAGE RENAL DISEASE; ETHNIC OR RACIAL ASPECTS; FAMILY HISTORY; GLOMERULUS FILTRATION RATE; HEMATURIA; HUMAN; HYPERTENSION; MASS SCREENING; PRACTICE GUIDELINE; PROTEINURIA; QUALITY OF LIFE; EARLY DIAGNOSIS; ECONOMICS; PATIENT SELECTION; RENAL INSUFFICIENCY; RISK FACTOR;

ASYMPTOMATIC DISEASES; EARLY DIAGNOSIS; HUMANS; MASS SCREENING; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY; RISK FACTORS;

EID: 84923936503     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02250314     Document Type: Article

References (37)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038–2047, 2007
2. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41: 1–12, 2003
3. McCullough K, Sharma P, Ali T, Khan I, Smith WC, MacLeod A, Black C: Measuring the population burden of chronic kidney disease: A systematic literature review of the estimated prevalence of impaired kidney function. Nephrol Dial Transplant 27: 1812–1821, 2012
4. Grams ME, Chow EK, Segev DL, Coresh J: Lifetime incidence of CKD stages 3-5 in the United States. Am J Kidney Dis 62: 245– 252, 2013
5. KDIGO CKD Work Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3: 1–150, 2013
6. Vassalotti JA, Li S, Chen SC, Collins AJ: Screening populations at increased risk of CKD: The Kidney Early Evaluation Program (KEEP) and the public health problem. Am J Kidney Dis 53[Suppl 3]: S107–S114, 2009
7. McGill JB, Brown WW, Chen SC, Collins AJ, Gannon MR: Kidney Early Evaluation Program (KEEP). Findings from a community screening program. Diabetes Educ 30: 196–198, 200–202, 206, 2004
8. McClellan WM, Ramirez SP, Jurkovitz C: Screening for chronic kidney disease: Unresolved issues. J Am Soc Nephrol 14[Suppl 2]: S81–S87, 2003
9. Qaseem A, Hopkins RH Jr., Sweet DE, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians: Screening,monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med 159: 835–847, 2013
10. Nielsen C, Lang RS: Principles of screening. Med Clin North Am 83: 1323–1337, v, 1999
11. Moreno JA, Martın-Cleary C, Gutierrez E, Rubio-Navarro A, Ortiz A, Praga M, Egido J: Haematuria: The forgotten CKD factor? Nephrol Dial Transplant 27: 28–34, 2012
12. Clinical Practice Guidelines we Can Trust. Available at: http://www.nap.edu/catalog.php?record_id513058. Accessed June 7, 2014
13. Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ: Chronic Kidney Disease Stages 1-3: Screening, Monitoring, and Treatment, Rockville, MD, Agency for Healthcare Research and Quality, 2012
14. Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ: Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: A systematic reviewfor theU.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 156: 570–581, 2012
15. Moyer VA; US Preventive Services Task Force: Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157: 567–570, 2012
16. Braithwaite RS: A piece of my mind. EBM’s six dangerous words. JAMA 310: 2149–2150, 2013
17. American Diabetes Association: Executive summary: Standards of medical care in diabetes—2011. Diabetes Care 34[Suppl 1]: S4–S10, 2011
18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., Jones DW, Materson BJ, Oparil S, Wright JT Jr., Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289: 2560–2572, 2003
19. Brosius FC 3rd, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, Pennathur S, Smith GL, Wilson PW; American Heart Association Kidney and Cardiovascular Disease Council; Council on High Blood Pressure Research; Council on Cardiovascular Disease in the Young; Council on Epidemiology and Prevention; Quality of Care and Outcomes Research Interdisciplinary Working Group: Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: A science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: Developed in collaboration with the National Kidney Foundation. Circulation 114: 1083–1087, 2006
20. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Kurella Tamura M, Feldman HI: KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 63: 713–735, 2014
21. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39[Suppl 1]: S1–S266, 2002
22. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR: Screening for proteinuria in US adults: A cost-effectiveness analysis. JAMA 290: 3101–3114, 2003
23. Hoerger TJ, Wittenborn JS, Segel JE, Burrows NR, Imai K, Eggers P, Pavkov ME, Jordan R, Hailpern SM, Schoolwerth AC, Williams DE; Centers for Disease Control and Prevention CKD Initiative: A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening. Am J Kidney Dis 55: 463–473, 2010
24. Craig JC, Barratt A, Cumming R, Irwig L, Salkeld G: Feasibility study of the early detection and treatment of renal disease by mass screening. Intern Med J 32: 6–14, 2002
25. Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, Dekker FW: Screening strategies for chronic kidney disease in the general population: Follow-up of cross sectional health survey. BMJ 333: 1047, 2006
26. Wu HY, Huang JW, Peng YS, Hung KY, Wu KD, Lai MS, Chien KL: Microalbuminuria screening for detecting chronic kidney disease in the general population: A systematic review. Ren Fail 35: 607–614, 2013
27. Clark WF, Macnab JJ, Sontrop JM, Jain AK, Moist L, Salvadori M, Suri R, Garg AX: Dipstick proteinuria as a screening strategy to identify rapid renal decline. J Am Soc Nephrol 22: 1729–1736, 2011
28. Collins AJ, Vassalotti JA, Wang C, Li S, Gilbertson DT, Liu J, Foley RN, Chen SC, Arneson TJ: Who should be targeted for CKD screening? Impact of diabetes, hypertension, and cardiovascular disease. Am J Kidney Dis 53[Suppl 3]: S71–S77, 2009
29. de Jong PE, Curhan GC: Screening, monitoring, and treatment of albuminuria: Public health perspectives. J Am Soc Nephrol 17: 2120–2126, 2006
30. Komenda P, Ferguson TW, Macdonald K, Rigatto C, Koolage C, Sood MM, Tangri N: Cost-effectiveness of primary screening for CKD: A systematic review. Am J Kidney Dis 63: 789–797, 2014
31. Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, Hallan HA, Lydersen S, Holmen J: International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 17: 2275–2284, 2006
32. Hoerger TJ, Wittenborn JS, Zhuo X, Pavkov ME, Burrows NR, Eggers P, Jordan R, Saydah S, Williams DE: Cost-effectiveness of screening for microalbuminuria among African Americans. J Am Soc Nephrol 23: 2035–2041, 2012
33. Kurella Tamura M, Li S, Chen SC, Cavanaugh KL, Whaley- Connell AT, McCullough PA, Mehrotra RL: Educational programs improve the preparation for dialysis and survival of patients with chronic kidney disease. Kidney Int 85: 686–692, 2014
34. Huang X, Carrero JJ: Better prevention than cure: Optimal patient preparation for renal replacement therapy. Kidney Int 85: 507–510, 2014
35. Uhlig K, Levey AS: Developing guidelines for chronic kidney disease:We should include all of the outcomes. Ann Intern Med 156: 599–601, 2012
36. Brown WW, Peters RM, Ohmit SE, Keane WF, Collins A, Chen SC, King K, Klag MJ, Molony DA, Flack JM: Early detection of kidney disease in community settings: The Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 42: 22–35, 2003
37. Vassalotti JA, Li S, Chen SC, Collins AJ: Screening populations at increased risk of CKD: the Kidney Early Evaluation Program (KEEP) and the public health problem. Am J Kidney Dis 53[Suppl 3]: S107–S114, 2009